Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $26 from $54 and keeps an Overweight rating on the shares. After the company received a Complete Response Letter from the FDA ...
Director Gregory Bailey reported purchasing 400,000 common shares of Biohaven Ltd. (NYSE:BHVN) on November 13, 2025. The shares were acquired at a price of $7.50, for a total transaction value of ...
The Oxford-Harrington Rare Disease Centre ('OHC') today announced the recipients of the 2025 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice.
A Novel Mouse Model of Ataxia Telangiectasia for Testing Small Molecule Readthrough (SMRT) Compounds
Investigator & Co-Director of the Neurotherapeutics IWI, Lundquist Institute (Formerly "LA BioMed"); Assistant Professor, David Geffen School of Medicine at UCLA Department of Neurology Ataxia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback